According to a recent study, schizophrenia patients who fail to comply with their medication regimens may have thoughts of suicide, increased resource utilization, such as hospitalization and associated expenditures, and clinical deterioration. This study will conduct a comprehensive review of therapies aimed at promoting treatment adherence among schizophrenia patients, with an emphasis on the evidence gained from their testing. Numerous therapies have concentrated on the drug, patient, and clinical service-related elements of treatment nonadherence. Several examples include LAI pharmaceutical formulations, behavioral therapy, and technology-assisted methamphetamine. LAI antipsychotics and behavioral strategies for integrating medication use into daily routines with electronic monitoring have been carefully examined. Although it is rare to see artificial intelligence (AI) implemented into mobile applications such as medicine tracking systems and voice assistants, the results of these experiments have been mixed at best. Patients with schizophrenia, who are notoriously difficult to treat, require randomized, controlled, blinded trials employing clinically relevant samples to evaluate not just adherence, but also clinically meaningful and lasting treatment outcomes.